A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 [RNA-loaded dendritic cell cancer vaccine] as a Vaccine in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.
Latest Information Update: 07 Jan 2012
At a glance
- Drugs Rocapuldencel T (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2012 Actual patient number is 26 according to ClinicalTrials.gov.
- 22 Dec 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.